Welcome to our dedicated page for Pavmed SEC filings (Ticker: PAVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PAVmed Inc. (PAVM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed, commercial-stage medical technology company. Through these documents, investors can review how PAVmed reports its operations in the medical device, diagnostics, and digital health sectors, along with detailed financial information and corporate actions.
Current reports on Form 8-K include items such as press releases announcing quarterly financial results and business updates. For example, PAVmed has filed an 8-K to furnish a press release covering financial results for the quarter ended September 30, 2025 and a related business update. These filings give context on revenue, operating expenses, non-GAAP measures such as EBITDA and adjusted loss, and commentary on the performance of subsidiaries like Lucid Diagnostics Inc. and Veris Health Inc.
Proxy materials such as the definitive proxy statement on Schedule 14A provide insight into corporate governance and stockholder proposals. PAVmed’s definitive proxy statement for a special meeting of stockholders describes proposals to approve a reverse stock split within a specified ratio range and a reduction in authorized common stock, along with the reasons for these actions, including efforts to meet Nasdaq’s minimum bid price requirement.
On this page, users can also monitor periodic reports such as Forms 10-Q and 10-K (when available), which contain comprehensive financial statements, management’s discussion and analysis, and risk factor disclosures. These filings are important for understanding PAVmed’s financial condition, capital structure, and its activities in medical technology development, commercialization, and digital health.
Stock Titan enhances access to these filings with AI-powered summaries that explain key points from lengthy documents, helping readers quickly identify information on topics such as quarterly performance, non-GAAP reconciliations, reverse stock split mechanics, and subsidiary operations. The platform also surfaces real-time updates from EDGAR, so new PAVM filings appear promptly as they are submitted.
Shaun O'Neil, Chief Operating Officer of PAVmed Inc. (PAVM), was granted 150,000 shares of restricted common stock on 09/30/2025 under the company’s Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan. The restricted shares carry a $0 purchase price and vest on May 20, 2028, and are subject to forfeiture if the required service period is not completed. After the grant, the reporting person beneficially owned 167,933 shares. The filing was reported on Form 4 and signed by power of attorney on 10/02/2025.